NRX Pharmaceuticals
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Employees
- -
- Market Cap
- $21M
- Website
- http://www.nrxpharma.com
- Introduction
NRX Pharmaceuticals, Inc. is a clinical-stage small molecule pharmaceutical company. It engages in developing of novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded on September 18, 2017 and is headquartered in Wilmington, DE.
NRx Pharmaceuticals announces CEO resignation and stockholder votes
NRx Pharmaceuticals' CEO Stephen Willard resigns to lead a biotech firm; Jonathan Javitt becomes Interim CEO. Stockholders re-elect directors, approve stock issuance, and authorize a potential reverse stock split. The company seeks a new CEO with commercial drug launch experience. HOPE Therapeutics plans to acquire a West Coast clinic, aiming for $100 million in annual revenue by mid-2025. NRx Pharmaceuticals achieves stability for NRX-100 and secures non-dilutive financing.
NRx Pharma announces 12-month real-time stability on first manufactured commercial scale
NRx Pharmaceuticals announced 12-month stability of NRX-100 (Ketamine) at Nephron Pharmaceuticals, supporting a US FDA new drug application for treating suicidal depression. NRX-100 is a preservative-free formulation, potentially avoiding toxic side effects, and is on track for NDA filing in 2024.
NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announces Completion of Twelve Months ...
NRx Pharmaceuticals announces 12-month stability of NRX-100 (ketamine) for treating suicidal depression, supporting FDA NDA submission. NRX-100 is the first preservative-free ketamine formulation, potentially avoiding toxic side effects.
© Copyright 2024. All Rights Reserved by MedPath